There's a lot to be optimistic about in the NA sector as 3 analysts just weighed in on HawkEye 360, Inc. (HAWK), SpaceX (SPCX) and Hemab Therapeutics Holdings, Inc. (COAG) with bullish sentiments.

TipRanks Welcomes a New ETF - NYSE:RANK

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

HawkEye 360, Inc. (HAWK)

In a report released today, Louie DiPalma from William Blair maintained a Buy rating on HawkEye 360, Inc.. The company's shares closed last Monday at $19.34, close to its 52-week low of $18.71.

According to TipRanks.com, DiPalma is a 4-star analyst with an average return of 6.0% and a 51.8% success rate. DiPalma covers the Technology sector, focusing on stocks such as Palantir Technologies, Science Applications, and Caci International.

HawkEye 360, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $37.86.

See the top stocks recommended by analysts >>

SpaceX (SPCX)

In a report released today, Douglas Harned from Bernstein maintained a Buy rating on SpaceX, with a price target of $239.00. The company's shares closed last Monday at $137.58.

According to TipRanks.com, Harned is a 4-star analyst with an average return of 12.9% and a 56.1% success rate. Harned covers the Industrial Goods sector, focusing on stocks such as L3Harris Technologies, Huntington Ingalls, and Northrop Grumman.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for SpaceX with a $241.36 average price target, implying a 66.8% upside from current levels. In a report issued on June 30, Wedbush also initiated coverage with a Buy rating on the stock with a $190.00 price target.

Hemab Therapeutics Holdings, Inc. (COAG)

Jefferies analyst Maury Raycroft maintained a Buy rating on Hemab Therapeutics Holdings, Inc. today and set a price target of $47.00. The company's shares closed last Monday at $40.75.

According to TipRanks.com, Raycroft is a 4-star analyst with an average return of 12.2% and a 44.2% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Corbus Pharmaceuticals, Dianthus Therapeutics, and Compass Therapeutics.

Hemab Therapeutics Holdings, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $43.80, which is a 14.1% upside from current levels. In a report issued on June 29, Wedbush also maintained a Buy rating on the stock with a $42.00 price target.

Analysts Are Bullish on Top NA Stocks: HawkEye 360, Inc. (HAWK), SpaceX (SPCX)